Sign in
CompletedNo phase

FMT for Patients With IBS With Fecal and Mucosal Microbiota Assessment

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
56 people enrolled
Started
12 Apr 2017
Ended
16 Dec 2023
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Fecal Microbiota Transplantation
  • Sham
  • Fecal and Mucosal Microbiota Assessment
Record updated
22 August 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Patients are aged 18 or above
  • Patients have a diagnosis of IBS consistent with the Rome III criteria (13)
  • Patients did not have adequate relief of global IBS symptoms and of IBS-related bloating at both the time of screening and the time of randomization
  • Patients had undergone clinical investigations with colonoscopy within five years of recruitment
  • Patients with written informed consent form provided

Who cannot take part

  • Patients have previous abdominal surgery (other than cholecystectomy or appendectomy)
  • Patients have used antibiotic therapy or anti-inflammatory drugs within the past 7 days
  • Patients have a history of inflammatory bowel disease or gastrointestinal malignancy
  • Patients have human immunodeficiency virus infection
  • Patients have a history of psychiatric illness (mania and schizophrenia)
  • Patients have anxiety defined by having a Generalized Anxiety Disorder 7 (GAD7) score > 10
  • Patients have active infection at the time of inclusion
  • Patients have renal disease manifested by 1.5 times the ULN of serum creatinine or blood urea nitrogen level
  • Patients have hepatic disease manifested by twice the upper limit of normal (ULN) for any of the following liver function tests: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or total bilirubin (except in isolated elevation of unconjugated bilirubin
  • Patients have diabetes mellitus manifested by HbA1C > 6.5%
  • Patients have abnormal thyroid function manifested by values of serum Sensitive Thyroid Stimulating Hormone and serum free T4 fall outside the reference range which is not controlled by thyroid medications
  • Patients have constipation predominant IBS (according to the definition of Rome III criteria)
  • Patients have depression defined by having a Patient Health Questionnaire-9 (PHQ-9) score > 15
  • Patients have any other organic causes that can explain the symptoms of IBS
  • Current pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Irritable bowel syndrome (IBS) is a common functional bowel disorder of the gastrointestinal tract affecting up to 20 percent of the adolescent and adult populations. It is characterised by abdominal pain, irregular bowel habits, altered stool consistencies and bloating, and is associated with impaired quality of life. IBS can be categorised into diarrhoea predominant type (IBS-D), constipation predominant type (IBS-C), and mixed type (IBS-M). Fecal microbiota transplantation (FMT) defined as infusion of feces from healthy donors to affected subjects has shown impressive results with high cure rates in patients with recurrent clostridium difficile infections. The investigators propose a randomised, placebo-controlled trial of FMT in patients with IBS.

The 2 groups in the trial

  • Fecal Microbiota TransplantationTreatment being tested

    FMT infusion and Fecal and Mucosal Microbiota Assessment

    Treatment: Fecal Microbiota Transplantation and Fecal and Mucosal Microbiota Assessment

  • Sham infusionSham treatment, for comparison

    Infusion with sham and Fecal and Mucosal Microbiota Assessment

    Treatment: Sham and Fecal and Mucosal Microbiota Assessment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomised, Placebo-controlled Study on Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome With Fecal and Mucosal Microbiota Assessment
Publications
Record updated
22 August 2024